Storys zum Thema Krebs

IEVA (Independent European Vape Alliance)

Beating cancer with Harm Reduction

Bruxelles (ots) - The Independent European Vape Alliance (IEVA) welcomes and supports the “EU Beating Cancer Plan” presented today by the European Commission. The plan is extremely important in order to significantly reduce the number of cancer-related deaths. However, the new EU strategy neglects an important instrument for public health: Harm Reduction. Almost one third of cancer cases in Europe are caused by smoking: “Tobacco consumption continues to be the leading ...

Fördergesellschaft IZB mbH

3

World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools

Technische Universität München

Sixfold increase in risk: study shows link between cervical cancer and HIV infection

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36390/ High resolution images: https://mediatum.ub.tum.de/1585216 NEWS RELEASE Sixfold increase in risk Link between cervical cancer and HIV infection A ...

Sysmex Inostics GmbH

Sysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...

Sysmex Inostics GmbH

Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study investigating the utility of cfDNA-based markers using the highly sensitive OncoBEAM RAS assay, an enhanced ...

Sysmex Inostics GmbH

Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...

Carl Zeiss Meditec AG

Effectiveness and efficiency of targeted intra-operative single dose radiotherapy for breast cancer patients confirmed

Jena, Germany (ots) - New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published [1] Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when ...

Sysmex Inostics GmbH

Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...

Technische Universität München

Improving immunotherapy for cancer

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36023/ High resolution images: https://mediatum.ub.tum.de/1544218 NEWS RELEASE Cause for the lack of immune defense against tumors discovered Improving immunotherapy for cancer One of the reasons why cancer develops is because regulatory cells inhibit the body's ...

Sysmex Inostics GmbH

Sysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing

Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...

Spectrum. The most dangerous artwork

On February 4 is World Cancer Day. German Cancer Aid and Dermatological Prevention Association demand: Sunbed Ban

Sysmex Inostics GmbH

Sysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment

Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...

Spectrum. The most dangerous artwork

The World's Most Dangerous Artwork / Cancer charity Deutsche Krebshilfe (German Cancer Aid), ADP, and the artistic duo LOW BROS welcomed guests to a somewhat unusual gallery opening

Sysmex Inostics GmbH

Sysmex Inostics announces first results of tissue-independent liquid biopsy for early stage breast cancer mutation characterization and monitoring using ultra-sensitive SafeSEQ technology

Hamburg, Germany and Baltimore, Maryland (ots) - New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas demonstrated a potential utility for monitoring ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI

Fördergesellschaft IZB mbH

The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB

Sysmex Inostics GmbH

Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development

Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...

Sysmex Inostics GmbH

Sysmex Inostics publishes first feasibility study of NGS-based liquid biopsy to complement early breast cancer screening by imaging

Hamburg/Baltimore (ots) - Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of Malaga [(IBIMA)-CIMES-UMA, Malaga Spain] and collaborators have published the first pilot study to examine the use of a non-invasive liquid ...

Sysmex Inostics GmbH

Sysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer

Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...

Sysmex Inostics GmbH

Liquid Biopsy performance comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS testing published in Scientific Reports (Nature Journal)

Hamburg, Germany (ots) - Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces publication of a study comparing the performance of plasma RAS mutation detection by two commercial liquid biopsy testing platforms, the OncoBEAM(TM) ...

Sysmex Inostics GmbH

Sysmex Inostics OncoBEAM(TM)-EGFR digital PCR liquid biopsy demonstrates two-fold higher detection of p.T790M mutations in 183 NSCLC patients in comparison study

Hamburg/Baltimore (ots) - Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer Institute (Lyon, France) comparing the performance of Sysmex Inostics BEAMing (beads, emulsion, amplification, and magnetics) assay for EGFR ...

Sysmex Inostics GmbH

Sysmex Inostics' SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM(TM) enhanced digital PCR technology for detection of mutations in circulating tumor DNA

Hamburg/Baltimore (ots) - Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics' novel ...

Technische Universität München

Black nanoparticles slow the growth of tumors

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 23325 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35324/ NEWS RELEASE Black nanoparticles slow the growth of tumors Melanin as a new diagnosis and treatment tool for tumors The dark skin pigment melanin protects us from the sun's damaging rays by ...

Mundipharma EDO

Mundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer

Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...